Rectal Adenocarcinoma Clinical Trials in New York, New York

4 studies are recruiting for rectal adenocarcinoma in New York, New York right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors

    The purpose of this study is to find out whether the study drug, TSR-042, followed by standard chemoradiotherapy (the chemotherapy drug capecitabine + radiation therapy) and standard surgery is an effective treatment for advanced dMMR solid tumors. The study will also look at the safety of the stud…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Memorial Sloan Kettering Cancer Center, New York, New York
    Locations
    10 in total
    Run by
    Memorial Sloan Kettering Cancer Center

    See if you can join NCT04165772 on ClinicalTrials.gov

  2. ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

    The purpose of ORACLE is to demonstrate the ability of a novel ctDNA assay developed by Guardant Health to detect recurrence in individuals treated for early-stage solid tumors. It is necessary that ctDNA test results are linked to clinical outcomes in order to demonstrate clinical validity for rec…

    Stage
    Not phased
    Ages
    18 and older
    Site
    Icahn School of Medicine at Mount Sinai, New York, New York
    Locations
    57 in total
    Run by
    Guardant Health, Inc.

    See if you can join NCT05059444 on ClinicalTrials.gov

  3. A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)

    Researchers are looking for other ways to treat locally advanced or metastatic colorectal cancer (mCRC) that is unresectable and has a gene mutation called KRAS G12C. Standard (or usual) treatments for this type of colorectal cancer may include mFOLFOX6 with or without bevacizumab. Researchers want…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Memorial Sloan Kettering Cancer Center ( Site 0095), New York, New York
    Locations
    236 in total
    Run by
    Merck Sharp & Dohme LLC

    See if you can join NCT06997497 on ClinicalTrials.gov

  4. A Study of Tucatinib and Trastuzumab in People With Rectal Cancer

    The study researchers believe that a combination of the drugs trastuzumab and tucatinib, given with standard chemotherapy (capecitabine and oxaliplatin/FOLFOX), may help participants with rectal cancer.

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York
    Locations
    7 in total
    Run by
    Memorial Sloan Kettering Cancer Center

    See if you can join NCT05672524 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.